Gastrointestinal disease control after histamine2-receptor antagonist dose modification for renal impairment in frail chronically Ill elderly patients

Journal of the American Geriatrics Society

Volumn 51, Issue 5, 2003, Pages 650-656

  Lackner, Thomas E ^a   Heard, Tom ^b   Glunz, Samantha ^c   Gann, Nicole ^d   Babington, Maude ^e   Malone, Daniel C ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b PFIZER INC   (United States)

^c Medical Center of Aurora   (United States)

^d Kaweah Delta Health Care District   (United States)

^e Babington Consulting   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aged; Dosage; Gastrointestinal diseases; Histamine H2 antagonists; Renal impairment

Indexed keywords

BISMUTH SALICYLATE; CIMETIDINE; CREATININE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; RANITIDINE;

AGE; AGED; AGITATION; ARTICLE; BODY WEIGHT; CHRONIC PATIENT; CONTROLLED STUDY; CREATININE CLEARANCE; DIGESTIVE SYSTEM ULCER; DISEASE CONTROL; DISORIENTATION; DOSE RESPONSE; DUODENUM ULCER; DYSPEPSIA; EMERGENCY WARD; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HALLUCINATION; HOSPITALIZATION; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENTAL DISEASE; MORTALITY; NEUROTOXICITY; NURSING HOME; PHYSICIAN; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; STOMACH ULCER; TREATMENT OUTCOME; UNITED STATES; VERTIGO;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; FEMALE; FRAIL ELDERLY; GASTROINTESTINAL DISEASES; HISTAMINE H2 ANTAGONISTS; HUMANS; KIDNEY FAILURE; MALE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0037732712     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0579.2003.00209.x     Document Type: Article

References (36)

1. Nielsen TM, Somani SK, Cooper SL et al. Acid-peptic disease drug-use review in six long-term care facilities. Consult Pharm 1994;9:1417-1426.
2. Lauritsen K, Laursen LS, Rask-Maden J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal disease (Part I). Clin Pharmacokinet 1990;19:11-31.
3. Lauritsen K, Laursen LS, Rask-Maden J. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal disease (Part II). Clin Pharmacokinet 1990;19:94-125.
4. 2-receptor antagonists. Standard therapy for acid-peptic diseases. N Engl J Med 1990;323:1672-1680.
5. U.S. Food and Drug Administration. Summary of Pepcid labeling changes [On-line]. Available at http://www.fda.gov/medwatch/safety/2001/pepcid_ summary.htm Accessed May 5, 2001.
6. Pepcid (famotidine) [package insert]. West Point, PA: Merck & Co, 1991.
7. Tagamet (cimetidine hydrochloride) [package insert]. Philadelphia, PA: SmithKline Beecham, 1996.
8. Axid (nizatidine) [package insert]. Indianapolis, IN: Eli Lilly & Company, 1996.
9. Zantac (ranitidine hydrochloride) [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc, 1997.
10. Canto TG, Korek JS. Central nervous system reactions to histamine-2 receptor blockers. Ann Intern Med 1991;114:1027-1034.
11. Schentag JJ, Cerra FB, Calleri G et al. Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet 1979;1:177-181.
12. Kimelblatt BJ, Cerra FB, Calleri G et al. Dose and serum concentration relationships in cimetidine-associated mental confusion. Gastroenterology 1980;78:791-795.
13. Slugg PH, Haug MT 3rd, Pippenger CE. Ranitidine pharmacokinetics and adverse central nervous system reactions. Arch Intern Med 1992;152:2325-2329.
14. Porter JB, Beard K, Walker AM et al. Intensive hospital monitoring study of intravenous cimetidine. Arch Intern Med 1986;146:2237-2239.
15. Kowalsky SF, Andritz MB, Calvert JF et al. A prospective evaluation of cimetidine drug use. Hosp Pharm 1989;24:105-108.
16. Cerra FB, Schentag JJ, McMillen M et al. Mental status, the intensive care unit, and cimetidine. Ann Surg 1982;196:565-570.
17. Naranjo CA, Busto U, Sellers EM et el. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
18. Ilet KF, Nation RL, Tjokresetio R et al. Pharmacokinetics of ranitidine in critically ill patients. Br J Clin Pharmacol 1986;21:279-288.
19. Roberts J, Tumer N. Pharmacodynamic basis for altered drug action in the elderly. Clin Geriatr Med 1988;4:127-149.
20. Jelliffe RW. Creatinine clearance: Bedside estimate. Ann Intern Med 1973;79:604-605.
21. O'Connell MB, Dwinell AM, Bannick-Mohrland SD. Predictive performance of equations to estimate creatinine clearance in hospitalized elderly patients. Ann Pharmacother 1992;26:627-635.
22. Winter ME. Basic principles. In: Winter ME, Koda-Kimble MA, Young LY, eds. Basic Clinical Pharmacokinetics, 2nd Ed. Spokane, WA: Applied Therapeutics, 1988, pp. 81-82.
23. Ducharme MP, Smythe M, Strohs G. Drug-induced alterations in serum creatinine concentrations. Ann Pharmacother 1993;27:622-633.
24. Sherman DS, Avorn J, Champion EW. Cimetidine use in nursing homes. Prolonged therapy and excessive doses. J Am Geriatr Soc 1987;35:1023-1027.
25. Vigneri S, Termini R, Leandro G et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995;333:1106-1110.
26. Soll AH. Peptic ulcer disease and its complications. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management, 6th Ed. Philadelphia, PA: Saunders, 1998, pp. 620-678.
27. Porro GB, Parente F. Long term treatment of duodenal ulcer. A review of management options. Drugs 1991;41:38-51.
28. Jorde R, Burhol PG, Hansen T. Ranitidine 150 mg at night in the prevention of gastric ulcer relapse. Postgrad Med J 1987;28:460-463.
29. Liedberg G, Davies HJ, Enskog L et al. Ulcer healing and relapse prevention by ranitidine in peptic ulcer disease. Scand J Gastroenterol 1985;20:941-944.
30. Alstead EM, Ryan FP, Holdsworth CD et al. Ranitidine in the prevention of gastric and duodenal ulcer relapse. Gut 1983;24:418-420.
31. 2-receptor antagonists and duodenal ulcer recurrence: Analysis of efficacy and commentary on safety, costs, and patient selection. Am J Gastroenterol 1987;82:1242-1249.
32. Walt R, Katschinski B, Logan R et al. Rising frequency of ulcer perforation in elderly people in the United Kingdom. Lancet 1986;1:489-492.
33. Kaplan RC, Heckbert SR, Koepsell TD et al. Risk factors for hospitalized gastrointestinal bleeding among older persons. J Am Geriatr Soc 2001;49:126-133.
34. Pahor M, Guralnik JM, Saljve ME et al. Disability and severe gastrointestinal hemorrhage: A prospective study of community-dwelling older persons. J Am Geriatr Soc 1994;42:816-825.
35. Katz PO. Gastroesophageal reflux disease. J Am Geriatr Soc 1998;46:1558-1565.
36. Gabrel CS. Characteristics of elderly nursing home current patients and discharges: Data from the 1997 National Nursing Home Survey. Adv Data 2000;312:1-15.